Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice

Journal of Alzheimer's Disease

Volumn 35, Issue 4, 2013, Pages 777-788

  Xiao, Chun ^a,b   Davis, Francesca J ^a,b   Chauhan, Balwantsinh C ^c   Viola, Kirsten L ^d   Lacor, Pascale N ^d   Velasco, Pauline T ^d   Klein, William L ^d   Chauhan, Neelima B ^a,b  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^c ROOSEVELT UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's immunotherapy; amyloid oligomer antibody; brain transit; cerebral amyloid immunocytochemistry; intranasal delivery; olfactory pathway; rostral migratory stream pathway; spatial acquisition learning; trigeminal pathway

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; OLIGOMER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG UPTAKE; FEMALE; GENE TARGETING; INTRANASAL DRUG ADMINISTRATION; MALE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPATIAL LEARNING; TRANSGENIC MOUSE;

EID: 84878855436     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122419     Document Type: Article

References (51)

1. Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P, de Leon M, Greenberg BD, Kukull W, Maruff P, Sperling RA, Stern Y, Touchon J, Vellas B, Andrieu S,Weiner MW, Carrillo MC, Bain LJ (2011) Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement 7, 127-132.
2. Khachaturian ZS, Khachaturian AS (2009) Prevent Alzheimer's disease by 2020: A national strategic goal. Alzheimers Dement 5, 81-84.
3. Bonda DJ, Lee HP, Lee HG, Friedlich AL, Perry G, Zhu X, SmithMA(2010) Novel therapeutics for Alzheimer's disease: An update. Curr Opin Drug Discov Devel 13, 235-246.
4. Finder VH, GlockshuberR(2007) Amyloid-beta aggregation. Neurodegener Dis 4, 13-27.
5. Kawahara M (2010) Neurotoxicity of beta-amyloid protein: Oligomerization, channel formation, and calcium dyshomeostasis. Curr Pharm Des 16, 2779-2789.
6. Menendez-Gonzalez M, Perez-Pinera P, Martinez-Rivera M, Muniz AL, Vega JA (2011) Immunotherapy for Alzheimer's disease: Rational basis in ongoing clinical trials. Curr Pharm Des 17, 508-520.
7. Holstein GR, Martinelli GP, Friedrich VL (2011) Anatomical observations of the caudal vestibulo-sympathetic pathway. J Vestib Res 21, 49-62.
8. Wisniewski T, Boutajangout A (2010) Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med 77, 17-31.
9. Fu HJ, Liu B, Frost JL, Lemere CA (2010) Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 9, 197-206.
10. Pul R, Dodel R, StangelM(2011) Antibody-based therapy in Alzheimer's disease. Expert Opin Biol Ther 11, 343-357.
11. Zhang Y, Lee DH (2011) Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist 17, 163-173.
12. Chauhan NB, Siegel GJ, Lichtor T (2004) Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRND8 mice. J Neurosci Res 78, 732-741.
13. Chauhan NB, Siegel GJ (2004) Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease. Expert Rev Vaccines 3, 717-725.
14. Chauhan NB (2007) Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res 85, 451-463.
15. Dhuria SV, Hanson LR, Frey WH 2nd (2010) Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 99, 1654-1673.
16. Malerba F, Paoletti F, Capsoni S, Cattaneo A(2011) Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin Drug Deliv 8, 1277-1296.
17. Kim TH, Park CW, Kim HY, Chi MH, Lee SK, Song YM, Jiang HH, Lim SM, Youn YS, Lee KC (2012) Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice. Biol Pharm Bull 35, 1076-1083.
18. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, Frey WH (2010) Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 13, 195-201.
19. Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T (2012) Effect of intranasal insulin on cognitive function: A systematic review. J Clin Endocrinol Metab 97, 366-376.
20. Apostolatos A, Song S, Acosta S, Peart M, Watson JE, Bickford P, Cooper DR, Patel NA (2012) Insulin promotes neuronal survival via the alternatively spliced protein kinase CdeltaII isoform. J Biol Chem 287, 9299-9310.
21. Subramanian S, John M (2012) Intranasal administration of insulin lowers amyloid-beta levels in rat model of diabetes. Indian J Exp Biol 50, 41-44.
22. Kullmann S, Frank S, Heni M, Ketterer C, Veit R, Haring HU, Fritsche A, Preissl H (2013) Intranasal insulin modulates intrinsic reward and prefrontal circuitry of the human brain in lean women. Neuroendocrinology 97, 176-182.
23. Paslakis G, Blum WF, Deuschle M (2012) Intranasal insulinlike growth factor I (IGF-I) as a plausible future treatment of depression. Med Hypotheses 79, 222-225.
24. Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A (2009) Development of a non invasive NGFbased therapy for Alzheimer's disease. Curr Alzheimer Res 6, 158-170.
25. Zhu W, Cheng S, Xu G, Ma M, Zhou Z, Liu D, Liu X (2011) Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia. Drug Deliv 18, 338-343.
26. Capsoni S, Marinelli S, Ceci M, Vignone D, Amato G, Malerba F, Paoletti F, Meli G, Viegi A, Pavone F, Cattaneo A (2012) Intranasal "painless" human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in APP X PS1 mice. PLoS One 7, e37555.
27. Tian L, Guo R,Yue X, Lv Q,Ye X,Wang Z, Chen Z,Wu B, Xu G, LiuX(2012) Intranasal administration of nerve growth factor ameliorate beta-amyloid deposition after traumatic brain injury in rats. Brain Res 1440, 47-55.
28. Jiang Y, Wei N, Lu T, Zhu J, Xu G, Liu X (2011) Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 172, 398-405.
29. Vaka SR, Murthy SN, Balaji A, Repka MA(2012) Delivery of brain-derived neurotrophic factor via nose-to-brain pathway. Pharm Res 29, 441-447.
30. Zhu J, Jiang Y, Xu G, Liu X (2012) Intranasal administration: A potential solution for cross-BBB delivering neurotrophic factors. Histol Histopathol 27, 537-548.
31. Furrer E, Hulmann V, Urech DM (2009) Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. J Neuroimmunol 215, 65-72.
32. Ye J, Shao H, Hickman D, Angel M, Xu K, Cai Y, Song H, Fouchier RA, Qin A, Perez DR (2010) Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin Vaccine Immunol 17, 1363-1370.
33. Frenkel D, Solomon B (2002) Filamentous phage as vectormediated antibody delivery to the brain. Proc Natl Acad Sci U S A 99, 5675-5679.
34. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM (2011) Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 6, e18296.
35. Thorne RG, Emory CR, Ala TA, FreyWH 2nd (1995) Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 692, 278-282.
36. Mistry A, Stolnik S, Illum L (2009) Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379, 146-157.
37. Veronesi MC,Kubek DJ,Kubek MJ(2011) Intranasal delivery of neuropeptides. Methods Mol Biol 789, 303-312.
38. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment:Apilot clinical trial. Arch Neurol 69, 29-38.
39. Whitman MC, Fan W, Rela L, Rodriguez-Gil DJ, Greer CA (2009) Blood vessels form a migratory scaffold in the rostral migratory stream. J Comp Neurol 516, 94-104.
40. Scranton RA, Fletcher L, Sprague S, Jimenez DF, Digicaylioglu M (2011) The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS. PLoS One 6, e18711.
41. Grill JD, Cummings JL (2010) Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother 10, 711-728.
42. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.
43. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP,Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24, 10191-10200.
44. Gomez D, Martinez JA, Hanson LR, Frey WH 2nd, Toth CC (2012) Intranasal treatment of neurodegenerative diseases and stroke. Front Biosci (Schol Ed) 4, 74-89.
45. Lochhead JJ, Thorne RG (2012) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64, 614-628.
46. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm 337, 1-24.
47. Johnson NJ, Hanson LR, Frey WH (2010) Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm 7, 884-893.
48. Curtis MA, Kam M, Nannmark U, Anderson MF, Axell MZ, Wikkelso C, Holtas S, van Roon-Mom WM, Bjork-Eriksson T, Nordborg C, Frisen J, DragunowM, Faull RL, Eriksson PS (2007) Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 315, 1243-1249.
49. SunW, Kim H, MoonY(2010) Control of neuronal migration through rostral migration stream in mice. Anat Cell Biol 43, 269-279.
50. Kam M, Curtis MA,McGlashan SR, Connor B, Nannmark U, Faull RL (2009) The cellular composition and morphological organization of the rostral migratory stream in the adult human brain. J Chem Neuroanat 37, 196-205.
51. Eom TY, Li J, Anton ES (2010) Going tubular in the rostral migratory stream: Neurons remodel astrocyte tubes to promote directional migration in the adult brain. Neuron 67, 173-175.